

Prahlad T Ram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9450231/publications.pdf>

Version: 2024-02-01

72
papers

10,456
citations

71102

41
h-index

102487

66
g-index

74
all docs

74
docs citations

74
times ranked

18732
citing authors

#	ARTICLE	IF	CITATIONS
1	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. <i>Cell Reports</i> , 2021, 34, 108726.	6.4	27
2	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. <i>Gynecologic Oncology</i> , 2021, 161, 104-112.	1.4	4
3	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. <i>Gynecologic Oncology</i> , 2021, 163, 181-190.	1.4	5
4	Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4450-4450.	7.0	0
5	Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor $\hat{\pm}$ Blockade in Uterine Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4449-4449.	7.0	0
6	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2352-2361.	4.1	5
7	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. <i>Cancer Research</i> , 2020, 80, 5554-5568.	0.9	29
8	GnRH-Râ€™ Targeted Lytic Peptide Sensitizes <i>BRCA</i> Wild-type Ovarian Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 969-979.	4.1	12
9	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 421-436.	4.1	10
10	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018, 78, 3233-3242.	0.9	69
11	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018, 9, 2923.	12.8	151
12	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. <i>Clinical Cancer Research</i> , 2017, 23, 7034-7046.	7.0	71
13	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. <i>JCI Insight</i> , 2017, 2, .	5.0	38
14	Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. <i>ELife</i> , 2016, 5, e10250.	6.0	681
15	Nextâ€™ generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. <i>Journal of Pathology</i> , 2016, 240, 84-95.	4.5	63
16	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. <i>Cell Reports</i> , 2016, 15, 1493-1504.	6.4	75
17	Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. <i>Cell Metabolism</i> , 2016, 24, 685-700.	16.2	293
18	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	12.8	100

#	ARTICLE	IF	CITATIONS
19	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1713-1724.	7.0	69
20	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , 2015, 1, 15001.	3.0	3
21	The ZNF304-integrin axis protects against anoikis in cancer. <i>Nature Communications</i> , 2015, 6, 7351.	12.8	48
22	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. <i>Genome Medicine</i> , 2015, 7, 21.	8.2	34
23	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 448-459.	7.0	48
24	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. <i>Genome Research</i> , 2015, 25, 257-267.	5.5	94
25	Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers. <i>PLoS ONE</i> , 2015, 10, e0140072.	2.5	9
26	Computational Approaches for Visualization and Integration of Omics Data. <i>Comprehensive Analytical Chemistry</i> , 2014, , 443-454.	1.3	0
27	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. <i>Molecular Systems Biology</i> , 2014, 10, 728.	7.2	255
28	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. <i>Cancer Cell</i> , 2014, 26, 863-879.	16.8	46
29	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 α and Oxidative Phosphorylation in Melanoma. <i>Cancer Research</i> , 2014, 74, 7037-7047.	0.9	161
30	Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2740-2750.	7.0	14
31	Cancer Systems Biology: a peek into the future of patient care?. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 167-176.	27.6	159
32	Notch3 Pathway Alterations in Ovarian Cancer. <i>Cancer Research</i> , 2014, 74, 3282-3293.	0.9	59
33	2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014, 5, 3459.	12.8	103
34	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	16.8	252
35	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014, 5, 3887.	12.8	456
36	Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 166-175.	1.4	31

#	ARTICLE	IF	CITATIONS
37	A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. <i>Journal of Hepatology</i> , 2014, 60, 1203-1211.	3.7	99
38	Mapping Network Motif Tunability and Robustness in the Design of Synthetic Signaling Circuits. <i>PLoS ONE</i> , 2014, 9, e91743.	2.5	7
39	Network Motifs in JNK Signaling. <i>Genes and Cancer</i> , 2013, 4, 409-413.	1.9	47
40	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013, 4, 2427.	12.8	363
41	Clinical Activity and Safety of Combination Therapy with Temezirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). <i>Clinical Cancer Research</i> , 2013, 19, 3611-3620.	7.0	46
42	The glucose deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. <i>Molecular Systems Biology</i> , 2012, 8, 596.	7.2	109
43	Bioinformatics and systems biology. <i>Molecular Oncology</i> , 2012, 6, 147-154.	4.6	22
44	NetWalker: a contextual network analysis tool for functional genomics. <i>BMC Genomics</i> , 2012, 13, 282.	2.8	99
45	Targeting Src in Mucinous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 5367-5378.	7.0	42
46	Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1596-1612.	6.3	44
47	Clinical Applications of Systems Biology Approaches. , 2011, , 409-428.		0
48	Patterns of human gene expression variance show strong associations with signaling network hierarchy. <i>BMC Systems Biology</i> , 2010, 4, 154.	3.0	24
49	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in <i>Braf</i> Mutant Human Cutaneous Melanoma Cells. <i>Cancer Research</i> , 2010, 70, 8736-8747.	0.9	222
50	Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15449-15454.	7.1	909
51	Use of Data-Biased Random Walks on Graphs for the Retrieval of Context-Specific Networks from Genomic Data. <i>PLoS Computational Biology</i> , 2010, 6, e1000889.	3.2	79
52	Identification of Optimal Drug Combinations Targeting Cellular Networks: Integrating Phospho-Proteomics and Computational Network Analysis. <i>Cancer Research</i> , 2010, 70, 6704-6714.	0.9	198
53	Systems Biology of the MAPK1,2 Network. <i>Systems Biology</i> , 2010, , 455-489.	0.1	2
54	Rapidly exploring structural and dynamic properties of signaling networks using PathwayOracle. <i>BMC Systems Biology</i> , 2008, 2, 76.	3.0	12

#	ARTICLE	IF	CITATIONS
55	The Signaling Petri Net-Based Simulator: A Non-Parametric Strategy for Characterizing the Dynamics of Cell-Specific Signaling Networks. PLoS Computational Biology, 2008, 4, e1000005.	3.2	81
56	Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C&Eraf and B&Eraf isoforms by FGFR and MC1R. FASEB Journal, 2008, 22, 1393-1403.	0.5	18
57	An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Molecular and Cellular Endocrinology, 2007, 270, 50-56.	3.2	41
58	Hypothesis Generation in Signaling Networks. Journal of Computational Biology, 2006, 13, 1546-1557.	1.6	26
59	De Novo Signaling Pathway Predictions Based on Protein-Protein Interaction, Targeted Therapy and Protein Microarray Analysis. Lecture Notes in Computer Science, 2006, , 108-118.	1.3	5
60	Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 2005, 4, 988-1004.	46.4	1,853
61	The G&Eo/i-coupled Cannabinoid Receptor-mediated Neurite Outgrowth Involves Rap Regulation of Src and Stat3. Journal of Biological Chemistry, 2005, 280, 33426-33434.	3.4	102
62	Formation of Regulatory Patterns During Signal Propagation in a Mammalian Cellular Network. Science, 2005, 309, 1078-1083.	12.6	329
63	The Signaling Petri Net-based Simulator: A Non-Parametric Strategy for Characterizing the Dynamics of Cell-Specific Signaling Networks. PLoS Computational Biology, 2005, preprint, e5.	3.2	0
64	Quantitative Information Management for the Biochemical Computation of Cellular Networks. Science Signaling, 2004, 2004, pl11-pl11.	3.6	29
65	Effectors of G&Eo Signaling. , 2003, , 605-607.		0
66	Overexpression of Tightly Regulated Proteins: Protein Phosphatase 2A Overexpression in NIH 3T3 Cells. Methods in Enzymology, 2002, 345, 551-555.	1.0	1
67	G Protein Pathways. Science, 2002, 296, 1636-1639.	12.6	1,110
68	MAP Kinase Phosphatase As a Locus of Flexibility in a Mitogen-Activated Protein Kinase Signaling Network. Science, 2002, 297, 1018-1023.	12.6	601
69	G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene, 2001, 20, 1601-1606.	5.9	122
70	Modulation of the Estrogen Response Pathway in Human Breast Cancer Cells by Melatonin. , 2001, , 343-358.		5
71	Expression patterns of novel genes during mouse preimplantation embryogenesis. Molecular Reproduction and Development, 1994, 37, 121-129.	2.0	142
72	Reporter Gene Expression in G2 of the 1-Cell Mouse Embryo. Developmental Biology, 1993, 156, 552-556.	2.0	181